In vitro sensitivity of acinetobacter baumannii and pseudomonas aeruginosa to carbapenems among intensive care unit patients

Advances in Experimental Medicine and Biology

Volumn 788, Issue , 2013, Pages 109-116

  Guzek, A ^a   Korzeniewski, K ^a   Nitsch Osuch, Aneta ^b,c   Rybicki, Z ^a   Prokop, E ^c  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c St Family Maternity Hospital   (Poland)

Author keywords

Acinetobacter baumannii; Carbapenems; Pseudomonas aeruginosa; Resistance; Sensitivity

Indexed keywords

CARBAPENEM DERIVATIVE; DORIPENEM; IMIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG EFFICACY; IN VITRO STUDY; INTENSIVE CARE UNIT; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE;

ACINETOBACTER BAUMANNII; PSEUDOMONAS AERUGINOSA;

EID: 84881045151     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-6627-3_17     Document Type: Article

References (21)

1. Chastre, J., Wunderink, R., Prokocimer, P., Lee, M., Kaniga, K., & Friedland, I. (2008). Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Critical Care Medicine, 36, 1089-1096. (Pubitemid 351482655)
2. Clinical and Laboratory Standards Institute. (2008). Performance standards for antimicrobial susceptibility testing; M100-S18, 18th informational supplement (CLSI). Wayne: Clinical and Laboratory Standards Institute. Food and Drug Administration (2011). FDA criteria. http://www.fda.gov. Accessed on 12 Aug 2011.
3. Hanberger, A., Arman, D., Gill, H., Jindrák, V., Kalenic, S., Kurcz, A., Licker, M., Naaber, P., Scicluna, E. A., Vanis, V., & Walther, S. M. (2009). Surveillance of microbial in European Intensive Care Units: A first report from the Care-ICU programme for improved infection control. Intensive Care Medicine, 35, 91-100.
4. Hoban, D. J., Jones, R. N., Yamane, N., Frei, R., Trilla, A., & Pignatari, A. C. (1993). In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagnostic Microbiology and Infectious Disease, 17, 299-305.
5. Ikeda, Y., Mamiya, T., Nishiyama, H., Narusawa, S., Koseki, T., Mouri, A., & Nabeshima, T. (2012). A permission system for carbapenem use reduced incidence of drug-resistant bacteria and cost of antimicrobials at a general hospital in Japan. Nagoya Journal of Medical Science, 74, 93-104.
6. Jones, R. (2010). Microbial etiologies of hospitalacquired bacterial pneumonia and ventilatorassociated bacterial pneumonia. Clinical Infectious Diseases, 51(Suppl 1), S81-S87.
7. Kollef, M., Shorr, A., Tabak, Y., Gupta, V., Liu, L., & Johannes, R. (2005). Epidemiology and outcomes of health-associated pneumonia: Results from a large US database of culture positive pneumonia. Chest, 128 (3854), 3854-3862. (Pubitemid 43062645)
8. Koziol-Montewska, M., Jaworska-Gromaszek, I., Biernacka, J., Pluta, A., Nidzwiadek, J., Kaczor, D., Ligieza, J., & Rudzki, S. (2011). Review of the effectiveness of an empirical antibiotic therapy in suspected ventilator-associated pneumonia. Anaesthesiology and Intensive Therapy, 83, 136-141.
9. Kübler, A., Durek, G., Zamirowska, A., Duszynska, W., Paysińska, W., Gaszyński, W., & Pluta, A. (2004). Severe sepsis in Poland-the results of online registration of 1043 cases. Medical Science Monitor, 10, 635-641.
10. Livermore, D., Hope, R., Brick, G., Lillie,M., & Reynolds, R. (2008). Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-2006. The Journal of Antimicrobial Chemotherapy, 62(Suppl 2), ii55-ii63.
11. Magnotti, L., Schroeppel, T., Fabian, T., Clement, L., Swanson, J., Ficher, P., Bee, T., Maisch, G., Minard, G., Zarzaur, B., & Croce, M. (2008). Reduction in inadequate empiric antibiotic therapy for ventilatorassociated pneumonia: Impact of a unit-specific treatment pathway. The American Surgeon, 74, 516-523.
12. Pillar, C. M., Torres, M. K., Brown, N. P., Shah, D., & Sahm, D. F. (2008). In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States. Antimicrobial Agents and Chemotherapy, 52, 4388-4399.
13. Poirel, L., & Nordmann, P. (2006). Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology. Clinical Microbiology and Infectious Diseases, 12, 826-836. (Pubitemid 44151282)
14. Roca, I., Espinal, P., Vila-Farres, X., & Vila, J. (2012). The Acinetobacter baumannii oxymoron: Commensal hospital dweller turned pan-drug-resistant menace. Frontiers in Microbiology, 3, 1-29.
15. Romanelli, R., Jesus, L., Clemente, V., Lima, S., Rezende, E., Couthinho, R., Moreira, L., Neves, F., & Bras, N. (2009). Outbreak of resistant Acinetobacter baumannii-measures and proposal for prevention control. Brazilian Journal of Infectious Diseases, 13, 341-347.
16. Rossolin, G., & Mantegnoli, E. (2008). Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clinical Microbiology and Infection, 14 (Suppl 6), 2-8.
17. The European Committee on Antimicrobial Testing. EUCAST criteria of antimicrobial susceptibility testing (2011). http://www.eucast.org/ antimicrobial-susceptibility-testing/.Accessed on 12 Aug 2011.
18. Urban, C., Segal-Mauer, S., & Rahal, J. (2003). Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clinical Infectious Diseases, 15, 1268-1274. (Pubitemid 36629937)
19. Vincent, J., Rello, J., Marschall, J., Silva, E., Anzureto, A., Martin, C., Moreno, R., Lipman, J., Gomersall, C., Sakr, Y., & Reinhart, K. (2009). International study of the prevalence and outcomes of infection in intensive care units. JAMA, 302, 2323-2329.
20. Vitkauskiene, A., Skrodeniene, E., Dambrauskiene, A., Baksyte, G., Macas, A., & Sakalauskas, R. (2011). Characteristics of carbapenem-resistant Pseudomonas aeruginosa strains in patients with ventilatorassociated pneumonia in intensive care units. Medicine (Kaunas), 47(2), 652-656.
21. Wisplinghoff, H., Bischoff, T., Tallent, S., Seifert, H., Wenzel, R., & Edmond, M. (2004). Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases, 39, 309-317. (Pubitemid 39050477)